Idera Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 91   

Articles published

IDRA 3.32 -0.12 (-3.49%)
price chart
Idera Pharmaceuticals: Is The Writing On The Wall?
Idera Pharmaceuticals (NASDAQ:IDRA) is one of those stocks that caught my attention recently. There are four reasons for my argument that the stock is a screaming buy: a) Several new hires in management, who came from ViroPharma.
Biotech Stocks in News - Celladon (CLDN), Idera Pharmaceuticals (IDRA ...  Wall Street Observer
Idera Pharmaceuticals: A Star In The Making (IDRA)
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) is a biotechnology company engaged in discovering and developing Toll-Like Receptors (TLRs) antagonists, novel-synthetic DNA and RNA based drug candidates.
Related articles »  
Idera Pharmaceuticals Going Into 2015 (IDRA)
Idera Pharmaceuticals Inc. (NASDAQ:IDRA) is set to enter 2015 with a number of important developments happening during the year.
Related articles »  
4 Melting Stocks Alert: Idera Pharmaceuticals (NASDAQ:IDRA), Genetic ...
Idera Pharmaceuticals Inc (IDRA) declared that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for IMO-8400, an antagonist of the endosomal Toll-like receptors (TLRs) 7, 8 and 9, for the treatment of diffuse large B-cell ...
Stock Report on Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
[Globe Newswire] Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)(TREND ANALYSIS) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for oncology and rare diseases, today ...
Investors Need to Be Considers- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA ...  StreetWise Report
Closing Bell Reports: Idera Pharmaceuticals, Inc. (IDRA), TE Connectivity ...  WallStreet Scope
Plummeting Stocks Alert: Idera Pharmaceuticals (NASDAQ:IDRA), Applied ...
Idera Pharmaceuticals Inc (IDRA) declared that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for IMO-8400, an antagonist of the endosomal Toll-like receptors (TLRs) 7, 8 and 9, for the treatment of diffuse large B-cell ...
Morning Fast Movers: Brocade Communications Systems, Inc. (BRCD), Idera ...
Idera Pharmaceuticals, Inc. (IDRA) of the Healthcare sector (Biotechnology) is down -1.45% already this morning, a change from open of -1.17%.
Idera's IMO-8400 an Orphan Drug for lymphoma (IDRA)
The FDA designates Idera Pharmaceuticals' (IDRA -2.4%) lead product candidate, IMO-8400, an Orphan Drug for the potential treatment of diffuse large B-cell lymphoma.
Idera Announces FDA Orphan Drug Designation for IMO-8400 for the Treatment ...  Benzinga
Analysts Bullish on Idera Pharmaceuticals (NASDAQ:IDRA)
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) was riding high at the start of this year at over $5.50 at the start of the year, backing down to $4 then getting back near these levels again at the end of February.
Idera Pharmaceuticals (IDRA): Today's Weak On High Volume Stock  TheStreet.com
Closing Bell Reports: Golar LNG Ltd. (GLNG), Idera Pharmaceuticals, Inc. (IDRA ...
Idera Pharmaceuticals, Inc. (IDRA) of the Healthcare sector (Biotechnology) closed the day at $3.44 gaining 2.38%, a change from open of 2.99% after trading at a volume of 1,247,552 shares.